EP3222280
Aukning á lífaðgengi lyfs í naltrexón-meðferð
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
2.12.2011EP published:
20.1.2021EP application number:
17156985.8
EP translation filed:
20.4.2021Grant published:
15.5.2021EPO information:
European Patent Register
Max expiry date:
1.12.2031Expiry date:
1.12.2026Next due date:
31.12.2026
Title:
INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY
Timeline
Today
2.12.2011EP application
20.1.2021EP Publication
20.4.2021Translation submitted
15.5.2021Registration published
1.12.2026Expires
Owner
Name:
Nalpropion Pharmaceuticals LLCAddress:
10 North Park Place, Suite 201, Morristown, NJ 07960, US
Inventor
Name:
FLANAGAN, ShawnAddress:
San Diego, CA 92128, US
Name:
DUNAYEVICH, EduardoAddress:
Westlake Village, CA 91362, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
419395 PDate:
3.12.2010Country:
US
Classification
Categories:
A61K 31/485, A61K 31/137, A61P 3/04
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 8.11.2021
Expires: 1.12.2022
Payer: Árnason Faktor ehf.
Number: 12
Paid: 30.11.2022
Expires: 1.12.2023
Payer: Árnason Faktor ehf.
Number: 13
Paid: 15.11.2023
Expires: 1.12.2024
Payer: Árnason Faktor ehf.
Number: 14
Paid: 28.11.2024
Expires: 1.12.2025
Payer: Árnason Faktor ehf.
Number: 15
Paid: 5.12.2025
Expires: 1.12.2026
Payer: Árnason Faktor ehf.